With a market capitalization of $42.5 billion, IQVIA Holdings Inc. (IQV) is a leading global provider of clinical research services, healthcare analytics, and technology solutions for the life sciences industry. Headquartered in Durham, North Carolina, the company helps pharmaceutical and biotechnology companies accelerate drug development, conduct clinical trials, analyze healthcare data, and commercialize innovative therapies.
The company is ready to release its FY2026 Q3 earnings before the market opens on Tuesday, Oct. 27. Ahead of the event, analysts expect IQVIA to report a profit of $2.95 per share on a diluted basis, up 8.1% year over year from $2.73 per share in the year-ago quarter. The company has exceeded consensus estimates in each of the four trailing quarters.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
Wall Street analysts expect the company’s diluted EPS to grow by 6.9% annually to $11.56 in the current fiscal year 2026, followed by an 11.9% improvement to $12.93 in fiscal 2027.
www.barchart.comOver the past 52 weeks, the stock has gained 29.1%, surpassing the S&P 500 Index ($SPX), which has increased by 15%, and the State Street Health Care Select Sector SPDR ETF’s (XLV) 16.4% return.
www.barchart.comIQVIA Holdings has benefited from improving demand for clinical research services, accelerating growth in healthcare analytics, and stronger-than-expected financial results. Moreover, growing adoption of AI-powered solutions and recovering demand for outsourced drug development have also strengthened its growth outlook.
On Oct. 7, IQVIA introduced its new Life Science Models at TechIQ 2026, a suite of AI-powered tools designed to predict clinical trial outcomes and improve drug development. Built using proprietary healthcare data and technologies such as NVIDIA Nemotron, with support from Amazon Web Services, the models help pharmaceutical companies optimize trial design, select patient groups and dosages, and identify potential risks before studies begin. In initial evaluations covering 50 trials and 270 endpoints, 85% of predictions were on target or clinically close, highlighting the potential to improve clinical development efficiency and decision-making.
Wall Street analysts have been very bullish about IQVIA’s future. Among the 21 analysts covering the stock, the consensus rating is “Strong Buy.” Opinions include 17 “Strong Buy,” one “Moderate Buy,” and three “Hold.” The mean price target of $291.80 implies a 12.7% upside from current price levels.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Big Tech Needs Power. Constellation Just Found a $1 Billion Buyer in Google. Uber’s ezCater Acquisition Looks Like a Smart Move to Diversify Revenue Streams Amazon Stock Has Been Flat for the Past Month, But AMZN Put Credit Spreads Have Worked Out Well HPE Stock Has Nearly Tripled. Here’s Why Wall Street Expects It to Reach $92.